Literature DB >> 2213103

Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study.

M E Nesbit1, E A Gehan, E O Burgert, T J Vietti, A Cangir, M Tefft, R Evans, P Thomas, F B Askin, J M Kissane.   

Abstract

A total of 342 previously untreated eligible children were entered into the first Intergroup Ewing's Sarcoma Study (IESS) between May 1973 and November 1978. In group I institutions, patients were randomized between treatment 1 (radiotherapy to primary lesion plus cyclophosphamide, vincristine, dactinomycin, and Adriamycin [doxorubicin; Adria Laboratories, Columbus, OH] [VAC plus ADR]) or treatment 2 (same as treatment 1 without ADR), and group II institutions randomized patients between treatment 2 or treatment 3 (same as treatment 2 plus bilateral pulmonary radiotherapy [VAC plus BPR]). The percentages of patients relapse-free and surviving (RFS) at 5 years for treatments 1, 2, and 3 were 60%, 24%, and 44%, respectively. There was strong statistical evidence of a significant advantage in RFS for treatment 1 (VAC plus ADR) versus 2 (VAC alone) (P less than .001) and 3 (P less than .05) and also of treatment 3 versus 2 (P less than .001). Similar significant results were observed with respect to overall survival. Patients with disease at pelvic sites have significantly poorer survival at 5 years than those with disease at nonpelvic sites (34% v 57%; P less than .001). Among pelvic cases, there was no evidence of differing survival by treatment (P = .81), but among nonpelvic cases, there was strong evidence of differing survival by treatment (P less than .001). The overall percentage of patients developing metastatic disease was 44%; the percentages by treatments 1, 2, and 3 were 30%, 72%, and 42%, respectively. The overall incidence of local recurrence was 15%, and there was no evidence that local recurrence rate differed by treatment. Patient characteristics related to prognosis, both with respect to RFS and overall survival experience, were primary site (nonpelvic patients were most favorable) and patient age (younger patients were more favorable).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2213103     DOI: 10.1200/JCO.1990.8.10.1664

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  83 in total

1.  Efficacy of Proton Beam Therapy in the Treatment of Ewing's Sarcoma of the Paranasal Sinuses and Anterior Skull Base.

Authors:  Stacey Tutt Gray; Yen-Lin Chen; Derrick T Lin
Journal:  Skull Base       Date:  2009-11

2.  Expanded Access Through Cancer Trials Support Unit to Children's Oncology Group Sarcoma Trial AEWS1031 for Adolescents and Young Adults.

Authors:  Leo Mascarenhas; Mason C Bond; Nita L Seibel
Journal:  J Adolesc Young Adult Oncol       Date:  2011-03       Impact factor: 2.223

3.  Patient-Reported Functional and Quality of Life Outcomes in a Large Cohort of Long-Term Survivors of Ewing Sarcoma.

Authors:  Bradley J Stish; Safia K Ahmed; Peter S Rose; Carola A Arndt; Nadia N Laack
Journal:  Pediatr Blood Cancer       Date:  2015-08-14       Impact factor: 3.167

4.  (Sub)periosteal Ewing's sarcoma of bone.

Authors:  P Wuisman; A Roessner; S Blasius; R Erlemann; W Winkelmann; J Ritter
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

5.  Ewing's sarcoma metastasis to the gastric wall in a 72-year-old patient.

Authors:  Laura Borodyansky Dodis; Michael William Bennett; David L Carr-Locke
Journal:  MedGenMed       Date:  2006-07-10

6.  Long-lasting multiagent chemotherapy in adult high-risk Ewing's sarcoma of bone.

Authors:  Selmin Ataergin; Ahmet Ozet; Luis Solchaga; Mustafa Turan; Murat Beyzadeoglu; Kaan Oysul; Fikret Arpaci; Seref Komurcu; Serdar Surenkok; Mustafa Ozturk
Journal:  Med Oncol       Date:  2008-11-07       Impact factor: 3.064

7.  Role of radiation therapy in the multidisciplinary management of Ewing's Sarcoma of bone in pediatric patients: An effective treatment for local control.

Authors:  Jose Luis Lopez; Patricia Cabrera; Rafael Ordoñez; Catalina Marquez; Gema Lucia Ramirez; Juan Manuel Praena-Fernandez; Maria Jose Ortiz
Journal:  Rep Pract Oncol Radiother       Date:  2011-03-12

8.  Primary orbital Ewing sarcoma family of tumors: a study of 12 cases.

Authors:  S Kaliki; S G Rathi; V A R Palkonda
Journal:  Eye (Lond)       Date:  2017-12-08       Impact factor: 3.775

9.  Changes in health status among aging survivors of pediatric upper and lower extremity sarcoma: a report from the childhood cancer survivor study.

Authors:  Neyssa Marina; Melissa M Hudson; Kendra E Jones; Daniel A Mulrooney; Raffi Avedian; Sarah S Donaldson; Rita Popat; Dee W West; Paul Fisher; Wendy Leisenring; Marilyn Stovall; Leslie L Robison; Kirsten K Ness
Journal:  Arch Phys Med Rehabil       Date:  2013-02-01       Impact factor: 3.966

10.  Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group.

Authors:  Richard B Womer; Daniel C West; Mark D Krailo; Paul S Dickman; Bruce R Pawel; Holcombe E Grier; Karen Marcus; Scott Sailer; John H Healey; John P Dormans; Aaron R Weiss
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.